Interleukin-23/ Interleukin -17 Axis in Chronic Spontaneous Urticaria: A Case- Control Study

2021 ◽  
Vol 30 (1) ◽  
pp. 169-174
Author(s):  
Lobna A. El-Korashi ◽  
Basma M. Elkholy ◽  
Hanaa M. El Maghraby
Keyword(s):  
Disease Severity ◽  
Serum Levels ◽  
Chronic Spontaneous Urticaria ◽  
Autologous Serum ◽  
Control Group ◽  
Interleukin 17 ◽  
Autologous Serum Skin Test ◽  
Interleukin 23 ◽  
Urticaria Activity Score ◽  
Control Study

Background: Chronic Spontaneous Urticaria (CSU) is a common health problem and its clear etiology is not established yet. Several theories have been tried to illustrate its etiology and pathogenesis. Autoantibodies and inflammatory cytokines like IL-23 and IL17 are hypothesized to take part in CSU pathogenesis and outcome. Objectives: To detect serum levels of IL-23 and IL-17A among CSU patients and to determine its correlation with disease severity and its relation to autoreactivity. Methodology: Serum levels of IL-23 and IL-17A were measured in 23 patients with CSU (CSU group) and 23 healthy controls (control group). In CSU group, Weekly Urticaria Activity Score (UAS7) was recorded to assess disease severity. Autologous Serum Skin Test (ASST) was performed to assess autoreactivity. CSU patients᾿ group was subdivided, based on ASST, into positive ASST (ASST+ ) and negative ASST (ASST- ) subgroups. Correlation of serum IL-23 & IL-17A levels, with UAS7 and ASST response were analyzed. Results: CSU group had higher serum IL-17A and IL-23 levels than control group (P=0.000). ASST+ CSU had higher serum IL-17A and IL-23 levels than ASSTones (P=0.000). Additionally, UAS7 was higher in ASST+ subgroup than ASST- subgroup (32+11.7 versus 16.27+ 9.92; P =0.005). There was significant positive correlation between disease severity and serum levels of both IL-17A and IL-23 among CSU patients (r= 0.626 & P= 0.001 and r=0.515 & P= .012, respectively). Conclusion: Increased serum IL-17A and IL-23 levels may constitute two major determinants of CSU pathogenesis and severity.

scholarly journals Interleukin 17 Receptor a Haplotype Analysis in Chronic Spontaneous Urticaria

2020 ◽  
Author(s):  
Hesham Nada ◽  
Ranya Hassan ◽  
Rasha Abd El-Hamed Ibrahim ◽  
Omnia Emad Abdelsalam ◽  
Amal Fathy ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Haplotype Analysis ◽  
Complex Trait ◽  
Chronic Spontaneous Urticaria ◽  
Autologous Serum ◽  
Interleukin 17 ◽  
Allelic Discrimination ◽  
Autologous Serum Skin Test ◽  
Urticaria Activity Score

Abstract Background: Chronic spontaneous urticaria (CSU) is a distressing skin disease. Family clustering and heterogeneity in the onset and progression indicate that susceptibility to CSU is a complex trait. In this study, we performed haplotype analysis for one of the key player gene, IL17RA, for CSU to test the association with disease susceptibility and severity.MethodsThe study included 70 CSU patients and 30 healthy controls. The severity of the disease was evaluated by autologous serum skin test (ASST) and urticaria activity score (UAS). ASST test was done and quality of life was assessed using a questionnaire. Allelic discrimination analysis for rs4819554 and rs879577 was performed using Real-Time Polymerase Chain Reaction technology.Results: Carriers of rs4819554*G were more prone to develop CSU than its counterpart (p = 0.039), while rs4819554*A allele displayed more severe phenotype in the form of more prolonged disease duration (p = 0.040), concurrent angioedema (p < 0.001), higher level of treatment (p < 0.001), and higher score of quality of life (p < 0.001). Additionally, homozygote patients with rs879577*CC were associated with angioedema (p < 0.001). Haplotype analysis revealed that cohorts with both rs4819554*A and rs879577*T conferred protection against developing CSU (OR = 0.07, 95%CI = 0.01 - 0.32, p = 0.001).Conclusions: Our results showed that IL17RA gene polymorphisms might contribute to the increased susceptibility to CSU.

scholarly journals Evaluation of Serum Substance P Level in Chronic Urticaria and Correlation with Disease Severity

2020 ◽  
Author(s):  
Javad Fadaee ◽  
Maryam Khoshkhui ◽  
Maryam Emadzadeh ◽  
Seyed Isaac Hashemy ◽  
Reza Farid Hosseini ◽  
...  
Keyword(s):  
Substance P ◽  
Serum Level ◽  
Chronic Urticaria ◽  
Healthy Subjects ◽  
Background Information ◽  
Autologous Serum ◽  
Control Group ◽  
Autologous Serum Skin Test ◽  
Urticaria Activity Score

Substance P (SP) is a neurotransmitter emitted from neurons that plays a role in the pathogenesis of itching conditions including chronic urticarial (CU). The present research aims to investigate the serum level of S.P among CU patients and compare them with healthy subjects and explore how it correlates with the severity of urticaria. The present research was conducted on 87 CU patients who visited the allergy clinic of Ghaem Hospital, Mashhad, Iran from October 2017 to June 2018. Besides, 86 healthy subjects were recruited as the control group. Background information of patient was collected including age, sex, duration of the disease and the co-occurrence of angioedema. S.P serum level was measured in two groups by ELISA method. In the patients group, the autologous serum skin test (ASST) was performed along with the urticaria evaluation questionnaire include Urticaria Activity Score 7 (UAS7), Urticaria Control Test (UCT) and Chronic Urticaria Quality of Life (CU-Q2OL). Among the patients, the SP serum level showed to be about two times higher than the healthy subjects (p˂0.001). SP showed to be increased as patients’ age grew (p=0.010). In patients with a positive ASST, SP level was higher (p=0.012). No correlation was found between SP and the presence of angioedema among patients. There was no correlation between the SP serum level and the scores obtained from urticaria evaluation questionnaires. SP among CU patients was higher than healthy subjects. SP was also higher among female, older and positive ASST patients. The SP value was not correlated with the severity of urticaria, angioedema. In conclusion, Using SP antagonist drugs could be a potential treatment for chronic urticaria.

scholarly journals Chronic spontaneous urticaria after BNT162b2 mRNA (Pfizer-BioNTech) vaccination against SARS-CoV-2

2022 ◽  
Vol 43 (1) ◽  
pp. 30-36 ◽  
Author(s):  
Eli Magen ◽  
Avi Yakov ◽  
Ilan Green ◽  
Ariel Israel ◽  
Shlomo Vinker ◽  
...  
Keyword(s):  
Messenger Rna ◽  
Multiple Logistic Regression Analysis ◽  
Allergic Diseases ◽  
Chronic Spontaneous Urticaria ◽  
Healthy Control Group ◽  
Autologous Serum ◽  
Control Group ◽  
Autologous Serum Skin Test ◽  
Healthy Control ◽  
New Onset

Background: The factors that trigger and exacerbate chronic spontaneous urticaria (CSU) are well known, but it is not unclear whether messenger RNA (mRNA) vaccination against severe acute respiratory syndrome coronavirus 2 can trigger new cases of CSU or a relapse of CSU after long-term remission. Objective: To study the clinical cases of patients with new-onset CSU and CSU in remission who relapsed within 3 months after BNT162b2 mRNA vaccination. Methods: All patients with a CSU diagnosis within 12 weeks of BNT162b2 mRNA vaccination were retrospectively identified and included in the new-onset CSU and the relapsed CSU groups. The first control group (CSU control group) retrospectively consisted of patients diagnosed with CSU in complete clinical remission for ≥ 6 months, with no CSU relapse after vaccination. The second control group (healthy control group) consisted of subjects who were fully vaccinated and without CSU, matched 1:2 for age and sex with patients with CSU. Results: Twenty-seven patients were included in the relapsed CSU group, 32 patients in the new-onset CSU group, 179 patients in the CSU control group, and 476 subjects in the healthy control group. The relapsed CSU and new-onset CSU groups had more allergic comorbidities overall (19 [70.4%] and 13 [40.6%], respectively) than the CSU control group and the healthy control group (50 [27.9%] and 110 [23.1%], respectively; p < 0.001). Multiple logistic regression analysis showed that a positive autologous serum skin test result, overall allergic comorbidities, and basopenia were positively associated with the probability of CSU relapse within 3 months after BNT162b2 mRNA vaccination (odds ratio [OR] 5.54 [95% confidence interval {CI}, 2.36‐13.02], p < 0.001); OR 6.13 [95% CI, 2.52‐14.89], p = 0.001; and OR 2.81 [95% CI, 1.17‐6.72, p = 0.020, respectively). Conclusion: It is possible that BNT162b2 mRNA vaccination serves as a provoking and/or relapsing factor of CSU in individuals with allergic diseases and/or predisposed autoimmunity.

Serum Human β-Defensin 2 Is Increased in Angioedema Accompanying Chronic Spontaneous Urticaria

2021 ◽  
pp. 1-6
Author(s):  
Thi Bich Tra Cao ◽  
Hyun-Young Cha ◽  
Eun-Mi Yang ◽  
Bo-Youn Choi ◽  
Hae-Sim Park ◽  
...  
Keyword(s):  
Mast Cell ◽  
Mast Cell Degranulation ◽  
Chronic Spontaneous Urticaria ◽  
Autologous Serum ◽  
Healthy Controls ◽  
Serum Samples ◽  
Autologous Serum Skin Test ◽  
Vitamin D Levels ◽  
Ige Mediated ◽  
Urticaria Activity Score

<b><i>Introduction:</i></b> Chronic spontaneous urticaria (CSU) is a common cutaneous disease caused by mast-cell degranulation. Human β-defensin 2 (HBD2) is a well-known antimicrobial peptide that is also a pruritogen inducing vascular permeability via non-IgE-mediated mast-cell degranulation. <b><i>Objective:</i></b> We investigated the associations between serum HBD2 levels and the clinical characteristics of CSU patients. <b><i>Methods:</i></b> Serum samples from 124 CSU patients and 56 healthy controls were screened for the levels of HBD2 and translationally controlled tumor protein (TCTP)_ by using ELISA. The urticaria activity score over 7 days (UAS7) was used to measure disease activity in CSU patients. Accompanying angioedema was self-reported. <b><i>Results:</i></b> Serum HBD2 levels were higher in the CSU group than in healthy subjects (median [interquartile range], 84.1 [43.5, 142.5] vs. 59.5 [26.7, 121.5], <i>p</i> = 0.034). In CSU patients, serum HBD2 level was negatively correlated with the peripheral basophil percentages (Spearman’s rho = −0.229, <i>p</i> = 0.01) and vitamin D levels (−0.262, <i>p</i> = 0.02), but positively correlated with TCTP levels (0.252, <i>p</i> = 0.006). In CSU patients, HBD2 level was higher in those with than without angioedema (101.7 [50.9, 184.2] vs. 66.7 [37.9, 132.0], <i>p</i> = 0.019). It did not differ by aspirin hypersensitivity or atopy status, or autologous serum skin test positivity. <b><i>Conclusion:</i></b> A known mast-cell degranulator, HBD2 was elevated in the sera from CSU patients compared to healthy controls and may be involved in the pathogenesis of accompanying angioedema.

Serum otolin-1 as a biomarker for benign paroxysmal positional vertigo: a case-control study

2021 ◽  
pp. 1-4
Author(s):  
D V K Irugu ◽  
A Singh ◽  
H Yadav ◽  
H Verma ◽  
R Kumar ◽  
...  
Keyword(s):  
Serum Level ◽  
Benign Paroxysmal Positional Vertigo ◽  
Case Control Study ◽  
Serum Levels ◽  
Case Control ◽  
Control Group ◽  
Positional Vertigo ◽  
The Difference ◽  
Control Study ◽  
Paroxysmal Positional Vertigo

Abstract Objectives This study aimed to evaluate serum otolin-1 levels in patients with benign paroxysmal positional vertigo and to compare these levels with healthy individuals. Method This was a case-control study. After obtaining institutional ethical committee clearance, the serum level of otolin-1 was calculated in adult individuals (18–75 years old) who were divided into group 1 (patients presenting with benign paroxysmal positional vertigo) and group 2 (healthy patients without benign paroxysmal positional vertigo as the control group). Data analysis was carried out to compare the serum levels in the cases and controls. A p-value less than 0.05 was considered significant. Results A total of 70 age-matched individuals (cases, n = 40; controls, n = 30) were included in the study. The mean serum level of otolin-1 was 636.8 pg/ml (range, 259–981 pg/ml) in the group of patients with benign paroxysmal positional vertigo and 236.2 pg/ml (range, 189–370 pg/ml) in the control group. The difference was statistically significant (p = 0.0000). Conclusion The serum levels of otolin-1 in patients with benign paroxysmal positional vertigo are significantly higher compared with individuals without benign paroxysmal positional vertigo.

scholarly journals Mannose-binding lectin serum levels and (Gly54asp) gene polymorphism in recurrent aphthous stomatitis: A case-control study

2021 ◽  
Vol 35 ◽  
pp. 205873842110644
Author(s):  
Shereen A Baioumy ◽  
Shaimaa H Fouad ◽  
Shaimaa A Abdalgeleel ◽  
Ahmed A Baiomy ◽  
Dina E Sallam ◽  
...  
Keyword(s):  
Case Control Study ◽  
Serum Levels ◽  
Case Control ◽  
Recurrent Aphthous Stomatitis ◽  
Mannose Binding Lectin ◽  
Aphthous Stomatitis ◽  
Control Group ◽  
Mannose Binding ◽  
Binding Lectin ◽  
Control Study

Objectives: Dysregulation of the immune response appears to play a significant role in recurrent aphthous stomatitis (RAS) development. The main objective of this case–control study is to investigate the blood levels of mannose-binding lectin (MBL) and the frequency of the MBL2 gene (gly54asp) polymorphism in RAS patients, including 40 RAS patients and 40 healthy controls. Methods: Serum MBL levels were determined by ELISA, while the PCR-restriction fragment length polymorphism was used in MBL2 genotyping. Results: The median serum MBL level was significantly lower in the RAS group than in the control group (975 ng/mL (545–1320) vs. 1760 ng/mL (1254–2134); p≤ 0.001). The MBL levels were significantly lower in the BB genotype, whereas they were significantly higher in the wild type AA with a median of 525 and 1340 ng/mL, respectively ( p =0.005). The B allele was expressed in significantly higher percentages of RAS patients than in controls. There was no significant association between MBL serum levels ( p=0.685) or MBL2 codon 54 genotypes ( p=0.382) with the type of ulcers. Conclusion: There was an association between low MBL serum levels and the variant allele B of the MBL2 (gly54asp) gene, and the susceptibility to RAS. As a result, potential novel therapeutic options for RAS patients with MBL deficiency should be investigated.

scholarly journals EVALUATION OF D-DIMER SERUM LEVELS AMONG PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA AND ITS CORRELATION WITH DISEASE SEVERITY.

2020 ◽  
pp. 1-3
Author(s):  
Aditi Jaiswal ◽  
Kiran Godse
Keyword(s):  
Disease Activity ◽  
Disease Severity ◽  
Rank Correlation ◽  
Serum Levels ◽  
Analysis Data ◽  
Control Group ◽  
Tertiary Referral Centre ◽  
Cross Sectional ◽  
Positive Correlation ◽  
D Dimer

Aims: To evaluate D-Dimer serum levels in patients with chronic urticaria and its correlation with disease activity. Settings and Design: Single centre Cross sectional prospective observational age & sex matched case-control study at Dermatology OPD of a tertiary referral centre. Methods and Material: This study was conducted from January 2018 to June 2019. We in-cluded 33 patients with CU and 30 controls . They were recruited from urticaria clinic. All cases were subjected to history taking, general and dermatological examination. The serum levels of D-Dimer were measured by Semiquantitative, immunofiltration kits. Statistical analysis: Data was analysed by Statistical Package for Social Sciences (SPSS) ver-sion 21.0. Tests used were Independent t test/Mann-Whitney Test, Chi-Square test/Fisher’s Exact test, Spearman rank correlation coefficient, Kolmogorov- Smirnov test.. Results: Patients with active CU had elevated D-Dimer serum levels (p<0.0001) when com-pared with the control group (papulo-squamous disorder). Of 33 CSU patients, D-dimer level was elevated in 19 patients (57.58%). There was statistically significant positive correlation between disease severity (UAS7) and plasma D-dimer level (p <.0001, r =0.935). Conclusions: This study showed elevated D-dimer levels in more than half of Indian patients with CSU. There was a positive correlation between plasma D-dimer levels and the severity of disease activity. Investigation for plasma D-dimer level may be an alternative objective way to evaluate disease severity in patients with CSU. Limitations: Low sample size . Semi quantitative method was used instead of ELISA for D-Dimer.

scholarly journals The Assessment of 25-Hydroxy Vitamin D Serum Level in Asthmatic Patients: A Case-Control Study

2017 ◽  
Vol 5 (2) ◽  
pp. 65-69
Author(s):  
Mohammad Rasoul Sharanjani ◽  
Ebrahim Nadi ◽  
Maryam Vasheghani ◽  
Mohammad Jafari ◽  
Jalal Poorolajal
Keyword(s):  
Vitamin D ◽  
Serum Levels ◽  
Control Group ◽  
Control Groups ◽  
Asthmatic Patients ◽  
25 Hydroxy Vitamin D ◽  
The Mean ◽  
25 Oh Vitamin D ◽  
And Control ◽  
Control Study

Background: The prevalence of vitamin D deficiency is increasing due to changes in lifestyle and dietary habits. The aim of this study was to compare the serum levels of 25-hydroxy vitamin D between patients with bronchial asthma and the healthy control group. Patients and Methods: In this case-control study, 45 patients with asthma and 45 healthy subjects were enrolled and the level of serum 25 (OH) vitamin D was measured in both groups. In addition, a welltrained observer assessed airway reversibility, peak flowmetry and spirometry in the participants. The data were statistically analyzed using t test, one-way analysis of variance (ANOVA), and chi-square test with Stata software (version 11). Results: The mean age (±SD) of participants were 49.06 ±16.43 and 46.13 ±16.10 years in case and control groups, respectively (P=.394). The prevalence of vitamin D deficiency was high in both groups (69% in case and 65.5% in control groups). The mean (±SD) serum 25 (OH) vitamin D was 16.24 (±14.98) ng/ml in case group and 17.70 (±16.07) ng/mL in control group (P=.657). We found a positive correlation between the levels of vitamin D and the amount of FEV1 (r=0.2). Conclusions: According to the present study, the mean serum levels of vitamin D differences were not statistically significant between asthmatic patients and control group. However, the results of this study showed a positive relationship between forced expiratory volumes in first second (FEV1) and vitamin D levels

Sign in / Sign up

Export Citation Format

Share Document